UK-CAB 28 – Late presenters
Friday 30 January 2009
At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1
Programme
| 09.45-10.00 | Coffee, registration and expenses |
| 10.00-10.15 | Welcome and announcements updates: BHIVA Rep, SG membership |
| 10.15-10.30 | Brief look at use of the UKCAB membership forum – Matthew Williams |
| 10.30-10.45 | “Late Presenters” BMS/Gilead patient education programme feedback – Michael Marr |
| 10.45-11.00 | Break |
| 11.00-11.15 | Conference feedback: HIV9 |
| 11.15-12.00 | Immunology: a rough guide – Dr Adrian Palfreeman, MRC Clinical Trials Unit |
| 12.00-12.30 | New MRC HIV Clinical trials – |
| 12.30-14.00 | Lunch |
| 14.00-15.30 | Company meeting: Tibotec |
| 15.00-15.45 | Break |
| 15.45-16.00 | UK-CAB AOB |
| 16.00 | Close |
Background Reading
TRAINING: Immunolgy introduction
Sections 1.5 to 1.9 from this online manual
http://i-base.info/ttfa/section-1/
The sections cover the basics about the organs of the body, the immune system and how HIV interacts with the immune system. It also covers CD4 counts and how to interpret CD4 results and how HIV progresses in different people.
IL-2 studies
IL-2 provides quick ‘AIDS rescue’, but effect does not always last
http://www.aidsmap.com/en/news/50662C38-EECE-4256-A1B4-E47F548FF37F.asp?type=preview
This article looks at IL2 and how it can be used to boost CD4 counts and how long this may be of benefit. Some of the side effects of LI2 are also discussed.
COMPANY MEETING: Tibotec
Darunavir
Darunavir European license extended to all treatment-experienced
http://www.aidsmap.com/en/news/98FE4A3B-894E-4F19-8C2E-887CE44E4505.asp?type=preview
Darunavir is comparable to lopinavir in treatment-naive patients
http://i-base.info/htb/2096
Etravirine:
Etravirine overview including comment on drug interaction
http://i-base.info/guides/3569
Who can use etravirine: understanding etravirine susceptibility: new weighted genotype score and phenotypic cut-offs
http://i-base.info/htb/600
Rilpivirine (TMC-278)
Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks
http://www.aidsmap.com/en/news/4458BE13-A6E2-49CA-B795-F5FA101509F2.asp?type=preview
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.